Friday, 16 October 2026European Markets

PEXIP HOLDING Stock Was Up By 10.07% On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with PEXIP HOLDING (PEXIP.OL) rising 10.07% to kr28.20 on Tuesday, after two successive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.19% to kr1,302.94, after two consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

PEXIP HOLDING's last close was kr25.62, 11.59% under its 52-week high of kr28.98.

About PEXIP HOLDING

Pexip Holding ASA, a video technology company, provides end-to-end video conferencing platform and digital infrastructure worldwide. The company offers self-hosted software application and as-a-service deployment options for enterprise video conferencing, built on its proprietary Infinity technology. Its interoperability solutions are integrated into Microsoft Teams, Skype for Business, and Google Hangouts. The company serves government, healthcare, education, finance, legal, judicial, and retail industries. Pexip Holding ASA was founded in 2011 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PEXIP HOLDING has a trailing twelve months EPS of kr-0.83.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -5.06%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

PEXIP HOLDING's EBITDA is 613.17.

Moving Average

PEXIP HOLDING's worth is higher than its 50-day moving average of kr26.12 and way above its 200-day moving average of kr22.16.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PEXIP HOLDING's stock is considered to be overbought (>=80).

More news about PEXIP HOLDING (PEXIP.OL).

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com